RT Journal Article
SR Electronic
T1 Robust Mendelian Randomization Analysis by Automatically Selecting Valid Genetic Instruments with Applications to Identify Plasma Protein Biomarkers for Alzheimer’s Disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.20.23286200
DO 10.1101/2023.02.20.23286200
A1 Yao, Minhao
A1 Miller, Gary W.
A1 Vardarajan, Badri N.
A1 Baccarelli, Andrea A.
A1 Guo, Zijian
A1 Liu, Zhonghua
YR 2023
UL http://medrxiv.org/content/early/2023/12/04/2023.02.20.23286200.abstract
AB Mendelian randomization (MR) uses genetic variants as instrumental variables (IVs) to infer the causal effect of a modifiable exposure on the outcome of interest by removing unmeasured confounding bias. However, some genetic variants might be invalid IVs due to violations of core IV assumptions. MR analysis with invalid IVs might lead to biased causal effect estimate and misleading scientific conclusions. To address this challenge, we propose a novel MR method that first Selects valid genetic IVs and then performs Post-selection Inference (MR-SPI) based on two-sample genome-wide summary statistics. We analyze 912 plasma proteins using the large-scale UK Biobank proteomics data in 54,306 participants and identify 7 proteins (TREM2, PILRB, PILRA, EPHA1, CD33, RET, CD55) significantly associated with the risk of Alzheimer’s disease. We employ AlphaFold2 to predict the 3D structural alterations of these 7 proteins due to missense genetic variations, providing new insights into their biological functions in disease etiology.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used openly available human data that were originally located at: https://gwas.mrcieu.ac.uk/ http://www.cardiogramplusc4d.org/data-downloads/ https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files https://www.covid19hg.org/ I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.